Jamie Hey, MD
Pulmonary Disease · North Chesterfield, VANPI 1548271406
Payments from drug & device makers
Across 544 payments — averaging $28.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- GSK$1K
- AstraZeneca$1K
- Actelion Pharmaceuticals US, Inc.$863
- Grifols USA, LLC$851
- Boehringer Ingelheim$768
- plus $5K from 32 others
What the payments were for
- Food & beverage$9,94597%
- Education$2583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 1 | $5,232 |
| GSK | 113 | $1,360 |
| AstraZeneca | 40 | $1,118 |
| Actelion Pharmaceuticals US, Inc. | 32 | $863 |
| Grifols USA, LLC | 36 | $851 |
| Boehringer Ingelheim | 34 | $768 |
| Mallinckrodt Hospital Products Inc. | 46 | $763 |
| Regeneron Healthcare Solutions, Inc. | 30 | $550 |
| Sanofi | 30 | $522 |
| Genentech USA, Inc. | 25 | $385 |
| Insmed, Inc. | 19 | $324 |
| Amgen | 15 | $291 |
| Vifor Pharma, Inc. | 14 | $272 |
| Mylan Specialty L.p. | 17 | $261 |
| ANI Pharmaceuticals, Inc. | 8 | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $203 |
| Electromed, Inc. | 13 | $155 |
| Paratek Pharmaceuticals, Inc. | 8 | $147 |
| Baxter Healthcare | 4 | $136 |
| Merck | 6 | $120 |
| Pulmonx Corporation | 5 | $119 |
| Philips North America LLC | 7 | $115 |
| Inogen, Inc. | 5 | $113 |
| Novartis | 5 | $83 |
| Pharming Healthcare, Inc. | 4 | $66 |
| Gilead | 4 | $61 |
| United Therapeutics Corporation | 3 | $54 |
| Intuitive Surgical | 1 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Atricure, Inc. | 1 | $34 |
| 3b Medical, Inc. | 1 | $23 |
| CSL Behring | 1 | $21 |
| Vapotherm Inc | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Viatris Specialty LLC | 1 | $15 |
| Bayer | 1 | $12 |
| Advanced Respiratory, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,435 in reported general payments places this provider in the 80th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 894 | $746,277 |
| OfevNintedanib Esylate | 58 | $729,446 |
| OpsumitMacitentan | 32 | $452,719 |
| UptraviSelexipag | 13 | $355,663 |
| Dupixent PenDupilumab | 41 | $196,696 |
| GlassiaAlpha-1-Proteinase Inhibitor | 18 | $160,570 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 221 | $152,668 |
| Spiriva RespimatTiotropium Bromide | 185 | $123,235 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 187 | $100,801 |
| Breo ElliptaFluticasone/Vilanterol | 142 | $73,883 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $52,848 |
| EliquisApixaban | 62 | $50,561 |
| NucalaMepolizumab | 11 | $40,577 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $25,543 |
| Spiriva HandihalerTiotropium Bromide | 18 | $19,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $768 | $1,005,348464 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $1,360 | $994,3061,305 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $863 | $808,38245 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $203 | $160,57018 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,118 | $79,661136 claims |
| Johnson & JohnsonXarelto | $18 | $12,91920 claims |
| MerckDulera | $120 | $5,68812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in North Chesterfield
- Adam KaiserNorth Chesterfield$67K
- Muhammad AtharNorth Chesterfield$25K
- Alice HerlihyNorth Chesterfield$18K
- Steven NathanFalls Church$2.5M
- Shilpa JohriRichmond$1.7M
- Omar MinaiHopewell$1.3M
- Vijay SubramaniamWilliamsburg$1.3M
- Rabih HalabiFalls Church$604K
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.